Todd C. Skaar
Biochemistry, Genetics and Molecular Biology · Indiana University
Estrogen and related hormone effectsPharmacogenetics and Drug MetabolismHealth Systems, Economic Evaluations, Quality of LifeColorectal Cancer Treatments and StudiesCancer Treatment and Pharmacology
Publications
394
Citations
13,102
Est. group size
—
Recurring co-author estimate
Active years
97
Publishing since 1929
Publication cadence
Publications per year over the last 10 years — averaging 20.2/year recently
Recent publications
- Assessing patient understanding of pharmacogenomic test results: a qualitative study
Pharmacogenomics · 2025
- Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants
Drug Metabolism and Disposition · 2025
- Educational and Equity Implications of Biomarker Testing and Targeted Therapy Access in NSCLC: Insights from the NIH All of Us Research Program
Journal of Cancer Education · 2025
- The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.
UNC Libraries · 2025
- Evaluation of Potential Racial Disparities in CYP2C19‐Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention
UNC Libraries · 2025
- Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors
JCO Precision Oncology · 2025
- Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
Cancer Research Communications · 2025
- Treatment delays and risk of metastatic progression in colorectal cancer patients undergoing curative surgery: Real-world evidence from a national claims database.
JCO Oncology Practice · 2025
- Table S3 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
- Table S2 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
- Data from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
- Table S7 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
- Table S4 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
- Table S1 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
- Table 2 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
2025
Publishes in
- PMC×18
- Clinical Pharmacology & Therapeutics×15
- Clinical and Translational Science×7
- Pharmacogenomics×7
- Journal of Clinical Oncology×7
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile